SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges

Immune checkpoint inhibitors targeting programmed cell death 1 (PD-1), programmed cell death ligand-1 (PD-L1), and others have shown potent clinical efficacy and have revolutionized the treatment protocols of a broad spectrum of tumor types, especially non–small-cell lung cancer (NSCLC). Despite the...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Hematol Oncol
Hlavní autoři: Chen, Yu, Gao, Min, Huang, Zhaoqin, Yu, Jinming, Meng, Xiangjiao
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2020
Témata:
Review
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7390199/
https://ncbi.nlm.nih.gov/pubmed/32723363
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-020-00940-z
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky